A New Era in Lung Cancer Detection: Coreline Soft and Mint Medical's Partnership

In a significant development for the medical technology sector, Coreline Soft and Mint Medical have announced a partnership aimed at advancing AI-enabled lung cancer screening. Following an extensive collaboration of over six months, the integration of Coreline Soft's AI imaging platform AVIEW with Mint Medical's flagship platform, mint Lesion, is set to transform the clinical workflow associated with lung cancer screening. This partnership could potentially alter detection processes not just in Germany, but also in other international markets.

The New Workflow: AI Integration

The partnership is designed to establish a comprehensive workflow that incorporates AI-driven pulmonary nodule detection, structured reporting, and multi-site reading management. The initial launch is focused on Germany, where the national health insurance began to reimburse LDCT-based lung cancer screenings in April 2026. However, the collaboration is also structured to expand into other countries with emerging structured screening programs.

Why Germany Now?

Germany’s robust national screening framework mandates a series of requirements, such as double readings, the use of CAD software, and stringent quality assurance measures, all while ensuring GDPR compliance. In this scenario, AI has shifted from being an optional tool to a necessary component of effective cancer screening. Hospitals are not only looking for high-performing algorithms, but also for an integrated system that streamlines detection and reporting.

Onur Özek, Managing Director at Mint Medical, emphasized this point, stating, "Our partnership addresses the specific needs of lung cancer screening by streamlining workflows and ensuring quality assurance and effective longitudinal follow-up. We are committed to making this integrated approach accessible to healthcare providers."

The AI Advantage

Coreline Soft's AVIEW has already made strides in healthcare, being applied to over 2.5 million clinical readings in 19 countries. The system is known for its ability to detect not just pulmonary nodules but also assess other conditions, including COPD and coronary artery calcification—all from a single low-dose chest CT scan. This multifaceted approach provides healthcare professionals with multiple insights without requiring additional imaging, ultimately reducing the workload on radiologists.

With mint Lesion, radiologists can access AI-driven data as part of their structured reporting and patient management workflow. This integration allows for the automatic incorporation of AI-derived findings into standard protocols, enhancing efficiency and consistency across lung cancer screening operations.

Transforming Healthcare Systems

Jin-Kook Kim, CEO of Coreline Soft, remarked, "By merging detection, reporting, and management into a single operational framework, this partnership turns AI into the backbone of healthcare systems, especially in lung cancer screening. It’s not just a technological upgrade; it’s a transformation of operational efficacy."

Implications for the Future

This partnership is not merely about improving detection; it lays the foundation for a replicable model that other nations can adopt as they establish their own screening programs. With the focus on quality assurance, effective follow-up strategies, and the integration of advanced technologies, aimed at meeting emerging healthcare demands, Coreline Soft and Mint Medical are setting a new standard in the industry.

Their collaboration showcases the potential of AI in enhancing medical diagnostics and patient outcomes while addressing the pressing challenges within the health care ecosystem. As these organizations forge ahead, they provide a glimpse into what the future of lung cancer screening could look like—efficient, integrated, and above all, effective in saving lives.

In conclusion, as the landscape of healthcare continues to evolve, partnerships like that of Coreline Soft and Mint Medical will be vital in navigating the complexities of disease management and detection. Their commitment to innovation and quality in lung cancer screening will potentially reshape care models worldwide.